CompletedNCT01081145
Continuing guanfacine or switching to placebo after an ADHD response in children and teens
About this title
Read the official source — NCT01081145This study evaluated the safety and effectiveness of Extended-release Guanfacine Hydrochloride for people with ADHD.
Medication studyAges 6–17Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Extended-release Guanfacine Hydrochloride for people with ADHD.
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Dothan and 80 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: May 11, 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 528
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01081145
- Official title
Show the full official title
A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised Withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Little Rock, United States · San Diego, United States
74 more locations
- Spring Valley, United States
- Wildomar, United States
- Bradenton, United States
- Gainesville, United States
- Hialeah, United States
- Jacksonville, United States
- Maitland, United States
- Orlando, United States
- Naperville, United States
- Indianapolis, United States
- New Orleans, United States
- Salisbury, United States
- Omaha, United States
- Las Vegas, United States
- New York, United States
- Durham, United States
- Columbus, United States
- Oklahoma City, United States
- Salem, United States
- Philadelphia, United States
- Austin, United States
- San Antonio, United States
- Richmond, United States
- Kirkland, United States
- Hoboken, Belgium
- Jette, Belgium
- Ghent, Belgium
- Brussels, Belgium
- Ham, Belgium
- Namur, Belgium
- Uccle, Belgium
- Vlezenbeek, Belgium
- Vancouver, Canada
- Ottawa, Canada
- Whitby, Canada
- Saskatoon, Canada
- Rouffach, France
- Montpellier, France
- Amiens, France
- Nice, France
- Dijon, France
- Paris, France
- Tours, France
- Tübingen, Germany
- Ulm, Germany
- München, Germany
- Würzburg, Germany
- Dorsten, Germany
- Mainz, Germany
- Jena, Germany
- Berlin, Germany
- Freiburg im Breisgau, Germany
- Rho, Italy
- Calambrone, Italy
- Catania, Italy
- Milan, Italy
- Padova, Italy
- Roma, Italy
- Almere Stad, Netherlands
- Maastricht, Netherlands
- Palma, Spain
- Donostia / San Sebastian, Spain
- Alcorcón, Spain
- Pamplona, Spain
- Barcelona, Spain
- Madrid, Spain
- Valencia, Spain
- Mölnlycke, Sweden
- Norwich, United Kingdom
- Sheffield, United Kingdom
- Welwyn Garden City, United Kingdom
- Grays, United Kingdom
- Liverpool, United Kingdom
- Stevenage, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Extended-release Guanfacine Hydrochloride for people with ADHD.
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Extended-release Guanfacine Hydrochloride.
Who was this study for?
Listed age limits: 6 years to 17 years.
